Innoviva, Inc. (INVA)
USD 17.34
(-2.14%)
USD 17.34
(-2.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 176.7 Million USD | -45.77% |
| 2022 | 209.99 Million USD | -44.02% |
| 2021 | 375.1 Million USD | 16.81% |
| 2020 | 321.12 Million USD | 30.35% |
| 2019 | 246.36 Million USD | 3.4% |
| 2018 | 238.25 Million USD | 29.76% |
| 2017 | 183.6 Million USD | 68.46% |
| 2016 | 108.98 Million USD | 245.12% |
| 2015 | 31.58 Million USD | 193.08% |
| 2014 | -33.92 Million USD | 79.91% |
| 2013 | -168.86 Million USD | -1199.05% |
| 2012 | -12.99 Million USD | 88.15% |
| 2011 | -109.73 Million USD | -40.11% |
| 2010 | -78.32 Million USD | 3.73% |
| 2009 | -81.36 Million USD | 12.71% |
| 2008 | -93.2 Million USD | 44.71% |
| 2007 | -168.56 Million USD | 5.92% |
| 2006 | -179.17 Million USD | -19.8% |
| 2005 | -149.55 Million USD | -44.65% |
| 2004 | -103.39 Million USD | -42.68% |
| 2003 | -72.46 Million USD | 12.78% |
| 2002 | -83.08 Million USD | -11.65% |
| 2001 | -74.41 Million USD | 28.4% |
| 2000 | -103.92 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 54.68 Million USD | 111.92% |
| 2024 Q1 | 25.8 Million USD | -31.23% |
| 2023 Q1 | 47.73 Million USD | 92.88% |
| 2023 Q4 | 37.52 Million USD | -58.47% |
| 2023 Q3 | 90.34 Million USD | 786.9% |
| 2023 Q2 | 10.18 Million USD | -78.66% |
| 2023 FY | 113.88 Million USD | -45.77% |
| 2022 Q1 | 77.72 Million USD | -25.64% |
| 2022 Q4 | 24.74 Million USD | 0.21% |
| 2022 FY | 209.99 Million USD | -44.02% |
| 2022 Q3 | 24.69 Million USD | -70.09% |
| 2022 Q2 | 82.55 Million USD | 6.21% |
| 2021 FY | 375.1 Million USD | 16.81% |
| 2021 Q1 | 79.48 Million USD | -6.26% |
| 2021 Q3 | 94.55 Million USD | -2.06% |
| 2021 Q4 | 104.52 Million USD | 10.55% |
| 2021 Q2 | 96.54 Million USD | 21.46% |
| 2020 Q1 | 76.11 Million USD | 3.36% |
| 2020 FY | 321.12 Million USD | 30.35% |
| 2020 Q2 | 75.79 Million USD | -0.43% |
| 2020 Q3 | 84.43 Million USD | 11.4% |
| 2020 Q4 | 84.78 Million USD | 0.42% |
| 2019 Q4 | 73.63 Million USD | 21.13% |
| 2019 Q3 | 60.79 Million USD | 1.73% |
| 2019 Q2 | 59.76 Million USD | 14.55% |
| 2019 FY | 246.36 Million USD | 3.4% |
| 2019 Q1 | 52.16 Million USD | -32.44% |
| 2018 FY | 238.25 Million USD | 29.76% |
| 2018 Q4 | 77.22 Million USD | 33.92% |
| 2018 Q1 | 40.69 Million USD | -38.72% |
| 2018 Q2 | 62.67 Million USD | 54.01% |
| 2018 Q3 | 57.66 Million USD | -8.0% |
| 2017 Q2 | 47.83 Million USD | 63.0% |
| 2017 FY | 183.6 Million USD | 68.46% |
| 2017 Q4 | 66.4 Million USD | 65.93% |
| 2017 Q3 | 40.02 Million USD | -16.32% |
| 2017 Q1 | 29.34 Million USD | -22.09% |
| 2016 Q3 | 27.91 Million USD | 7.89% |
| 2016 Q4 | 37.66 Million USD | 34.9% |
| 2016 Q1 | 17.53 Million USD | 1.38% |
| 2016 Q2 | 25.87 Million USD | 47.6% |
| 2016 FY | 108.98 Million USD | 245.12% |
| 2015 Q4 | 17.29 Million USD | 105.04% |
| 2015 Q2 | 5.1 Million USD | 585.64% |
| 2015 Q1 | 745 Thousand USD | 473.08% |
| 2015 Q3 | 8.43 Million USD | 65.11% |
| 2015 FY | 31.58 Million USD | 193.08% |
| 2014 FY | -33.92 Million USD | 79.91% |
| 2014 Q4 | 130 Thousand USD | 101.36% |
| 2014 Q3 | -9.54 Million USD | 2.57% |
| 2014 Q2 | -9.79 Million USD | 85.22% |
| 2014 Q1 | -66.24 Million USD | -36.72% |
| 2013 Q1 | -33.38 Million USD | -11.36% |
| 2013 Q4 | -48.45 Million USD | -7.1% |
| 2013 Q3 | -45.23 Million USD | -8.26% |
| 2013 Q2 | -41.78 Million USD | -25.16% |
| 2013 FY | -168.86 Million USD | -1199.05% |
| 2012 FY | -12.99 Million USD | 88.15% |
| 2012 Q1 | 86.04 Million USD | 341.86% |
| 2012 Q3 | -33.35 Million USD | 6.61% |
| 2012 Q4 | -29.98 Million USD | 10.1% |
| 2012 Q2 | -35.7 Million USD | -141.5% |
| 2011 Q2 | -23.65 Million USD | -11.06% |
| 2011 Q3 | -29.2 Million USD | -23.44% |
| 2011 Q4 | -35.57 Million USD | -21.82% |
| 2011 FY | -109.73 Million USD | -40.11% |
| 2011 Q1 | -21.3 Million USD | -18.79% |
| 2010 Q1 | -21.11 Million USD | -2.59% |
| 2010 Q4 | -17.93 Million USD | 9.63% |
| 2010 Q3 | -19.84 Million USD | -2.13% |
| 2010 FY | -78.32 Million USD | 3.73% |
| 2010 Q2 | -19.43 Million USD | 7.96% |
| 2009 FY | -81.36 Million USD | 12.71% |
| 2009 Q4 | -20.57 Million USD | 2.38% |
| 2009 Q2 | -21.35 Million USD | -16.38% |
| 2009 Q1 | -18.34 Million USD | -18.57% |
| 2009 Q3 | -21.08 Million USD | 1.27% |
| 2008 FY | -93.2 Million USD | 44.71% |
| 2008 Q1 | -30.3 Million USD | 10.48% |
| 2008 Q4 | -15.47 Million USD | 24.96% |
| 2008 Q3 | -20.62 Million USD | 23.09% |
| 2008 Q2 | -26.81 Million USD | 11.52% |
| 2007 Q3 | -34.75 Million USD | 27.14% |
| 2007 FY | -168.56 Million USD | 5.92% |
| 2007 Q2 | -47.7 Million USD | 8.71% |
| 2007 Q4 | -33.84 Million USD | 2.62% |
| 2007 Q1 | -52.25 Million USD | -26.77% |
| 2006 FY | -179.17 Million USD | -19.8% |
| 2006 Q4 | -41.22 Million USD | 0.54% |
| 2006 Q1 | -51.68 Million USD | -17.7% |
| 2006 Q2 | -44.81 Million USD | 13.3% |
| 2006 Q3 | -41.44 Million USD | 7.51% |
| 2005 Q1 | -33.07 Million USD | -19.06% |
| 2005 Q3 | -39.37 Million USD | -18.64% |
| 2005 FY | -149.55 Million USD | -44.65% |
| 2005 Q4 | -43.91 Million USD | -11.52% |
| 2005 Q2 | -33.19 Million USD | -0.35% |
| 2004 Q2 | -26.14 Million USD | 0.0% |
| 2004 Q3 | -23.32 Million USD | 10.8% |
| 2004 Q4 | -27.78 Million USD | -19.13% |
| 2004 FY | -103.39 Million USD | -42.68% |
| 2003 FY | -72.46 Million USD | 12.78% |
| 2002 FY | -83.08 Million USD | -11.65% |
| 2001 FY | -74.41 Million USD | 28.4% |
| 2000 FY | -103.92 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 174.496% |
| Alkermes plc | 414.12 Million USD | 57.329% |
| Agenus Inc. | -159.54 Million USD | 210.755% |
| Aptorum Group Limited | -10.52 Million USD | 1779.212% |
| Ardelyx, Inc. | -63.27 Million USD | 379.267% |
| Dyadic International, Inc. | -8.22 Million USD | 2247.201% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 14924.581% |
| Lantern Pharma Inc. | -17.87 Million USD | 1088.44% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 979.596% |
| Novavax, Inc. | -566.51 Million USD | 131.193% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 342.137% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 314.985% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 1010.003% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 1772.905% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 432.62% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 146.442% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 827.0% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 566.632% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 236.996% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 310.583% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 1107.52% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 501.52% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 811.274% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 227.1% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 162.624% |
| AlloVir, Inc. | -181.33 Million USD | 197.451% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 186.199% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 703.968% |
| Bicycle Therapeutics plc | -189.94 Million USD | 193.031% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 202.868% |
| ChromaDex Corporation | -5.59 Million USD | 3256.081% |
| Chimerix, Inc. | -93.06 Million USD | 289.877% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 492.013% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 252.258% |
| CRISPR Therapeutics AG | -222.53 Million USD | 179.406% |
| Precision BioSciences, Inc. | -43.73 Million USD | 504.036% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 192.755% |
| Fortress Biotech, Inc. | -142.34 Million USD | 224.144% |
| Fortress Biotech, Inc. | -142.34 Million USD | 224.144% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 280.88% |
| ImmuCell Corporation | -5.74 Million USD | 3174.228% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 231.452% |
| Immix Biopharma, Inc. | -16.14 Million USD | 1194.776% |
| Incyte Corporation | 620.52 Million USD | 71.523% |
| IO Biotech, Inc. | -91.44 Million USD | 293.245% |
| Jaguar Health, Inc. | -34.29 Million USD | 615.322% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 203.983% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -1379.727% |
| ContextLogic Inc. | -328 Million USD | 153.875% |
| MiMedx Group, Inc. | 37.11 Million USD | -376.099% |
| MEI Pharma, Inc. | 14.54 Million USD | -1115.163% |
| NextCure, Inc. | -67.63 Million USD | 361.261% |
| Onconetix, Inc. | -36.03 Million USD | 590.387% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 523.62% |
| Opthea Limited | -191.84 Million USD | 192.111% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 6521.52% |
| Vaxcyte, Inc. | -468.04 Million USD | 137.755% |
| PDS Biotechnology Corporation | -43.04 Million USD | 510.519% |
| Precigen, Inc. | -88.92 Million USD | 298.721% |
| Pharming Group N.V. | -4.87 Million USD | 3721.424% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 205.616% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 693.86% |
| PureTech Health plc | -146.19 Million USD | 220.869% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 962.374% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 175.004% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 827.0% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 164.491% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 702.999% |
| Acelyrin, Inc. | -422.06 Million USD | 141.868% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 1370474.736% |
| Summit Therapeutics Inc. | -89.73 Million USD | 296.921% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 576.767% |
| Senti Biosciences, Inc. | -92.72 Million USD | 290.569% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 253.964% |
| Elevation Oncology, Inc. | -45.44 Million USD | 488.841% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 615.683% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 4582.67% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 5688.52% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 635.141% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 2178.685% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 359.881% |
| Seer, Inc. | -103.46 Million USD | 270.794% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 368.722% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 345.658% |
| ESSA Pharma Inc. | -32.13 Million USD | 649.911% |
| GlycoMimetics, Inc. | -39.27 Million USD | 549.924% |
| GT Biopharma, Inc. | -13.57 Million USD | 1401.628% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 180.608% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 482.024% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -103.554% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 411.332% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 443.084% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 1878.178% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 135.039% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 2661.743% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 448.587% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 168.054% |
| Aptose Biosciences Inc. | -52.35 Million USD | 437.514% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 1325.378% |
| Soligenix, Inc. | -7.69 Million USD | 2395.536% |
| Century Therapeutics, Inc. | -146.54 Million USD | 220.583% |
| Kura Oncology, Inc. | -165.8 Million USD | 206.577% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 289.079% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 2224.162% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 7220.657% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 2825.308% |
| Autolus Therapeutics plc | -195.02 Million USD | 190.607% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 308.735% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 339.892% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 936.097% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 177.833% |
| GRI Bio, Inc. | -11.38 Million USD | 1651.849% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 4013.201% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 234.694% |
| IGM Biosciences, Inc. | -263.46 Million USD | 167.072% |
| INmune Bio, Inc. | -29.74 Million USD | 694.16% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 259.751% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 564.104% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 1205.858% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 1220.48% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 389.222% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 264.347% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 164.024% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 186.964% |
| Verastem, Inc. | -92.08 Million USD | 291.9% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 474.9% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 195.962% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 249.273% |
| Histogen Inc. | -10.64 Million USD | 1760.331% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 1242.124% |
| Surrozen, Inc. | -45.78 Million USD | 485.996% |
| Organovo Holdings, Inc. | -15.08 Million USD | 1271.344% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 3571.529% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 398.085% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 444.502% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 799.007% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 2415.114% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 203.168% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 464.74% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 325.956% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 1260.972% |
| Apollomics, Inc. | -54.83 Million USD | 422.262% |
| Amarin Corporation plc | -67.58 Million USD | 361.45% |
| Mesoblast Limited | -58.79 Million USD | 400.556% |
| Turnstone Biologics Corp. | -59.03 Million USD | 399.344% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 206.753% |
| Synaptogenix, Inc. | -8.31 Million USD | 2225.476% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 1311.497% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 292.722% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 3787.994% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 2100.955% |
| Exelixis, Inc. | 170.88 Million USD | -3.408% |
| Better Therapeutics, Inc. | -38.26 Million USD | 561.839% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 213.959% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 134.172% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1596.638% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 2297.352% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 689.167% |
| Gritstone bio, Inc. | -154.63 Million USD | 214.276% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 356.617% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 1131.995% |
| Avid Bioservices, Inc. | -18.67 Million USD | 1046.081% |
| Insmed Incorporated | -709.62 Million USD | 124.902% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 1226.268% |
| MediWound Ltd. | -15.29 Million USD | 1255.716% |
| OmniAb, Inc. | -69.41 Million USD | 354.554% |
| Alector, Inc. | -151.74 Million USD | 216.455% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 263.645% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 438.861% |
| Zai Lab Limited | -366.57 Million USD | 148.206% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 155.783% |
| Aura Biosciences, Inc. | -84.99 Million USD | 307.915% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 171.98% |
| Immunic, Inc. | -99.22 Million USD | 278.093% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 223.436% |
| Veracyte, Inc. | -85.79 Million USD | 305.967% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 162.704% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 1343.554% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 2665.481% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 1040.311% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 69.458% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 794.256% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -355.412% |
| TG Therapeutics, Inc. | 20.63 Million USD | -756.439% |
| Galecto, Inc. | -39.9 Million USD | 542.824% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 519.996% |
| Fortrea Holdings Inc. | 63.1 Million USD | -180.046% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 225.821% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 711.916% |
| XBiotech Inc. | -37.51 Million USD | 571.098% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 356.617% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 363.273% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 263.762% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 788.334% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 431.586% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 131.045% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 325.13% |
| Vaxxinity, Inc. | -58.28 Million USD | 403.181% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 270.389% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 894.086% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 304.486% |
| NexImmune, Inc. | -29.19 Million USD | 705.324% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 3244.214% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 1311.881% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 95.634% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 794.092% |
| Scopus BioPharma Inc. | -11.71 Million USD | 1608.415% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 239.073% |
| Ainos, Inc. | -13.2 Million USD | 1438.056% |
| Pluri Inc. | -22.15 Million USD | 897.495% |
| Prothena Corporation plc | -191.03 Million USD | 192.5% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 228.015% |
| Celularity Inc. | -192.28 Million USD | 191.899% |
| Rallybio Corporation | -78.93 Million USD | 323.875% |
| Cue Biopharma, Inc. | -52.14 Million USD | 438.854% |
| MeiraGTx Holdings plc | -137.06 Million USD | 228.927% |
| Omeros Corporation | -164.53 Million USD | 207.402% |
| Humacyte, Inc. | -100.04 Million USD | 276.626% |
| Immunocore Holdings plc | -59.64 Million USD | 396.248% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 1052.147% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 821.762% |
| Blueprint Medicines Corporation | -486.27 Million USD | 136.339% |
| CalciMedica, Inc. | -21.87 Million USD | 907.813% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 336.685% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 234.395% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 203.161% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 154.056% |
| Pulmatrix, Inc. | -14.74 Million USD | 1298.84% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 594.36% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 298.849% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 134.293% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 361.593% |
| Cytokinetics, Incorporated | -496.2 Million USD | 135.612% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 613.405% |
| Nutriband Inc. | -4.87 Million USD | 3727.087% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 505.175% |
| Vor Biopharma Inc. | -126.03 Million USD | 240.205% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 95.834% |
| Evogene Ltd. | -26.39 Million USD | 769.581% |
| ProKidney Corp. | -151.52 Million USD | 216.623% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 373.819% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 2397.237% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 129.094% |
| CorMedix Inc. | -48.95 Million USD | 460.942% |
| BioLineRx Ltd. | -49.69 Million USD | 455.594% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 254.773% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 564.144% |
| Atai Life Sciences N.V. | -125.47 Million USD | 240.837% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 316.451% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 317.063% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 170.971% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 674.85% |
| MediciNova, Inc. | -9.9 Million USD | 1884.892% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 239.831% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 2539.903% |
| GeoVax Labs, Inc. | -26.74 Million USD | 760.769% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 176.225% |
| Biomea Fusion, Inc. | -126.13 Million USD | 240.095% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 150.575% |
| Mereo BioPharma Group plc | -28.41 Million USD | 721.864% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 192.475% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 176.845% |
| Absci Corporation | -115.51 Million USD | 252.975% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 740.552% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 256.564% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 172.971% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 801.338% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 184.959% |
| Allakos Inc. | -196.05 Million USD | 190.132% |
| Imunon, Inc. | -21.03 Million USD | 940.254% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 259.681% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -64.714% |
| BioAtla, Inc. | -129.68 Million USD | 236.258% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1596.638% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 1215.376% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 153.918% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 523.174% |
| XOMA Corporation | -41.84 Million USD | 522.264% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 267.915% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 245.445% |
| aTyr Pharma, Inc. | -54.91 Million USD | 421.763% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 302.122% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 202.221% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 169.447% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 923.204% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 2251.641% |
| Akari Therapeutics, Plc | -16.8 Million USD | 1151.464% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 1998385.655% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 47.653% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 2804.445% |
| UroGen Pharma Ltd. | -65.53 Million USD | 369.637% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 297.931% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 2532.999% |
| Orgenesis Inc. | -53.63 Million USD | 429.46% |
| Entera Bio Ltd. | -8.89 Million USD | 2087.504% |
| GH Research PLC | -41.22 Million USD | 528.676% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 787.37% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 312.767% |
| Xencor, Inc. | -138.63 Million USD | 227.46% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 3528.192% |
| Replimune Group, Inc. | -234.77 Million USD | 175.268% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 922.242% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 1366.55% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 2804.445% |
| Portage Biotech Inc. | -18.25 Million USD | 1068.109% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 2539.903% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 268.357% |
| OncoCyte Corporation | -25.13 Million USD | 803.012% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1663.125% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 1642.359% |
| Purple Biotech Ltd. | 22.27 Million USD | -693.449% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 2452.356% |
| scPharmaceuticals Inc. | -55.39 Million USD | 418.992% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 1035.082% |
| HilleVax, Inc. | -133.34 Million USD | 232.52% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 1566.586% |
| Tharimmune, Inc. | -9.45 Million USD | 1968.904% |
| Genprex, Inc. | -31.07 Million USD | 668.643% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 193.897% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 663.18% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 23199.216% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 3344.201% |
| OKYO Pharma Limited | -15.74 Thousand USD | 1122081.139% |
| Savara Inc. | -60 Million USD | 394.481% |
| Curis, Inc. | -48.33 Million USD | 465.615% |
| Daré Bioscience, Inc. | -30.83 Million USD | 672.989% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 3486.995% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 2528.322% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 748.473% |
| BeiGene, Ltd. | -1.2 Billion USD | 114.631% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 986.235% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 136.271% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 288.687% |
| Erasca, Inc. | -141.52 Million USD | 224.861% |
| bluebird bio, Inc. | -244.26 Million USD | 172.344% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 4003.468% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 9.119% |
| DBV Technologies S.A. | -76.43 Million USD | 331.198% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 4003.468% |
| Moderna, Inc. | -4.23 Billion USD | 104.169% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 514.722% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 2878.443% |
| Molecular Templates, Inc. | -10.46 Million USD | 1788.41% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 362.815% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 146.904% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 223.305% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 439.871% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 214.344% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 184.903% |
| MacroGenics, Inc. | -168.24 Million USD | 205.031% |
| RenovoRx, Inc. | -11.39 Million USD | 1650.623% |
| Adicet Bio, Inc. | -152.03 Million USD | 216.227% |
| Prime Medicine, Inc. | -191.29 Million USD | 192.377% |
| Aditxt, Inc. | -26.06 Million USD | 778.022% |
| Adagene Inc. | -23.71 Million USD | 844.983% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2517.327% |
| Quantum-Si incorporated | -111.17 Million USD | 258.952% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 658.358% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 1312.181% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -44.827% |
| SciSparc Ltd. | -5.77 Million USD | 3160.956% |
| Vericel Corporation | -6.46 Million USD | 2833.741% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 2141.306% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 864.326% |
| Generation Bio Co. | -138.56 Million USD | 227.53% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 312.825% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 304.382% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 173.293% |
| Invivyd, Inc. | -207.78 Million USD | 185.045% |
| Relay Therapeutics, Inc. | -373 Million USD | 147.375% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 1984.192% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -722.629% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 1817.789% |
| 2seventy bio, Inc. | -216.7 Million USD | 181.544% |
| ADMA Biologics, Inc. | 21.63 Million USD | -716.887% |
| Clene Inc. | -40.54 Million USD | 535.888% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 833.907% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 422.485% |
| GeoVax Labs, Inc. | -26.74 Million USD | 760.769% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 150.48% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 581.076% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -999.142% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 270.401% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 619.702% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 203.777% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 125.823% |
| Evaxion Biotech A/S | -22.19 Million USD | 896.094% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 314.5% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 179.198% |
| Trevena, Inc. | -35.28 Million USD | 600.762% |
| Surrozen, Inc. | -45.78 Million USD | 485.996% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 321.038% |
| Cingulate Inc. | -22.75 Million USD | 876.429% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -2258.636% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 495.614% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 2246.105% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 272.302% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 340.817% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 384.675% |
| Clearmind Medicine Inc. | -8.74 Million USD | 2121.53% |
| Kronos Bio, Inc. | -121.83 Million USD | 245.046% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 331.914% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 6124.886% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 275.26% |
| Statera Biopharma, Inc. | -98.34 Million USD | 279.685% |
| ImmunityBio, Inc. | -362.25 Million USD | 148.781% |
| Korro Bio, Inc. | -84.53 Million USD | 309.039% |
| Kineta, Inc. | -15.72 Million USD | 1223.889% |
| BioVie Inc. | -32.17 Million USD | 649.134% |
| Codexis, Inc. | -68.06 Million USD | 359.603% |
| Celularity Inc. | -192.28 Million USD | 191.899% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 179.381% |
| Celcuity Inc. | -66.23 Million USD | 366.81% |
| Virax Biolabs Group Limited | -6.49 Million USD | 2820.076% |
| Cibus, Inc. | -318.88 Million USD | 155.415% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 510.951% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 622.128% |
| IN8bio, Inc. | -30.33 Million USD | 682.487% |
| Kodiak Sciences Inc. | -277.32 Million USD | 163.72% |
| Annexon, Inc. | -143.72 Million USD | 222.951% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 242.748% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 373.349% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 853.749% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 149.956% |
| Eyenovia, Inc. | -25.4 Million USD | 795.528% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -441.388% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 3277.077% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 323.306% |
| Arcellx, Inc. | -89.88 Million USD | 296.605% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 489.124% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 228.79% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 668.032% |
| Moolec Science SA | -6.65 Million USD | 2755.759% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 389.033% |
| Geron Corporation | -193.94 Million USD | 191.113% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 508.547% |
| Royalty Pharma plc | 1.49 Billion USD | 88.157% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 207.643% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1994.42% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 907.087% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 203.365% |
| Humacyte, Inc. | -100.04 Million USD | 276.626% |
| Structure Therapeutics Inc. | -102.77 Million USD | 271.938% |
| 89bio, Inc. | -151.2 Million USD | 216.868% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 320.522% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 1315.33% |
| Genelux Corporation | -24.16 Million USD | 831.26% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 620.912% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 202.887% |
| Notable Labs, Ltd. | -14.65 Million USD | 1305.629% |
| Liquidia Corporation | -73.38 Million USD | 340.8% |
| Mustang Bio, Inc. | -50.72 Million USD | 448.36% |
| Immunovant, Inc. | -282.7 Million USD | 162.506% |
| Quantum-Si incorporated | -111.17 Million USD | 258.952% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 326.251% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 930.907% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 273.224% |
| Acasti Pharma Inc. | -11.31 Million USD | 1662.138% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 870.945% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 1205.858% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 182.553% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 4916.177% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 1212.357% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 706.06% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 526.998% |
| PepGen Inc. | -84.76 Million USD | 308.467% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 696.365% |
| United Therapeutics Corporation | 1.18 Billion USD | 85.087% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 871.756% |
| Solid Biosciences Inc. | -104.31 Million USD | 269.399% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 638.614% |
| Immuneering Corporation | -58.41 Million USD | 402.517% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 3571.529% |
| Silo Pharma, Inc. | -3.85 Million USD | 4683.187% |
| Belite Bio, Inc | -31.66 Million USD | 658.005% |
| XOMA Corporation | -41.84 Million USD | 522.264% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 361.714% |
| Bionomics Limited | -17.89 Billion USD | 100.988% |
| Apogee Therapeutics, Inc. | -93 Million USD | 290.004% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -395.261% |
| uniQure N.V. | -282.87 Million USD | 162.47% |
| Cassava Sciences, Inc. | -105.95 Million USD | 266.774% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2517.327% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 236.451% |
| Forte Biosciences, Inc. | -32.48 Million USD | 643.954% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 2226.781% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 701.153% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 3277.077% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 1343.554% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 2087.951% |
| Altimmune, Inc. | -95.92 Million USD | 284.208% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 340.44% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -395.261% |
| Compugen Ltd. | -12.99 Million USD | 1460.137% |
| Peak Bio, Inc. | -1356.23 USD | 13029527.162% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 456.239% |
| Benitec Biopharma Inc. | -22.49 Million USD | 885.723% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 172.929% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 694.06% |
| Zura Bio Limited | -62.63 Million USD | 382.111% |
| PolyPid Ltd. | -22.86 Million USD | 872.769% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 1185.703% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 694.06% |
| Instil Bio, Inc. | -159.16 Million USD | 211.02% |
| argenx SE | -425.04 Million USD | 141.574% |
| Immunome, Inc. | -109.53 Million USD | 261.334% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 450.871% |
| Verona Pharma plc | -67.83 Million USD | 360.514% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 778.085% |
| Shattuck Labs, Inc. | -91.95 Million USD | 292.165% |
| CervoMed Inc. | -7.81 Million USD | 2361.761% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 341.703% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 1426.545% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 466.814% |
| Moolec Science SA | -6.65 Million USD | 2755.759% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 1174.321% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 230.676% |
| AnaptysBio, Inc. | -164.41 Million USD | 207.48% |
| Design Therapeutics, Inc. | -78.19 Million USD | 325.999% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 303.018% |
| NeurAxis, Inc. | -6.66 Million USD | 2751.499% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 536.329% |
| Lumos Pharma, Inc. | -36.61 Million USD | 582.627% |
| Achilles Therapeutics plc | -75.25 Million USD | 334.814% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 778.085% |
| 180 Life Sciences Corp. | -13.47 Million USD | 1411.141% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -3327.043% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 6124.886% |
| Nutriband Inc. | -4.87 Million USD | 3727.087% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 259.513% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 418.687% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 447.606% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 367.34% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 426.495% |
| Palisade Bio, Inc. | -13.07 Million USD | 1452.02% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 489.15% |
| Beam Therapeutics Inc. | -176.48 Million USD | 200.127% |
| Neurogene Inc. | -55.58 Million USD | 417.919% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 261.89% |
| AEON Biopharma, Inc. | -48.42 Million USD | 464.883% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 282.721% |
| Sesen Bio, Inc. | -25.9 Million USD | 782.037% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 311.554% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 1503.912% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 138.368% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 343.942% |
| Athira Pharma, Inc. | -125.46 Million USD | 240.842% |
| Vaccinex, Inc. | -22.88 Million USD | 872.161% |
| HCW Biologics Inc. | -25.71 Million USD | 787.125% |
| XOMA Corporation | -41.84 Million USD | 522.264% |
| Nektar Therapeutics | -137.42 Million USD | 228.586% |
| Arvinas, Inc. | -401.5 Million USD | 144.012% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 1998385.655% |
| Merus N.V. | -156.54 Million USD | 212.879% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 276.249% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 610.425% |
| Rezolute, Inc. | -70.42 Million USD | 350.925% |
| Clene Inc. | -40.54 Million USD | 535.888% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 1178.91% |
| BeyondSpring Inc. | -23.11 Million USD | 864.511% |
| Synlogic, Inc. | -55.16 Million USD | 420.351% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 1085.604% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 1732.567% |
| Peak Bio, Inc. | -1356.23 USD | 13029527.162% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 536.286% |
| Krystal Biotech, Inc. | -109.72 Million USD | 261.044% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 236.413% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 151.517% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 3823.362% |
| MannKind Corporation | 8.67 Million USD | -1936.287% |
| Ikena Oncology, Inc. | -75.41 Million USD | 334.309% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 1931.751% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 362.842% |
| Gossamer Bio, Inc. | -183.75 Million USD | 196.163% |
| CohBar, Inc. | -12.38 Million USD | 1526.419% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 448.374% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 740.552% |
| Legend Biotech Corporation | -439.48 Million USD | 140.208% |
| Mural Oncology plc | -194.63 Million USD | 190.789% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 363.183% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 1194.494% |
| Disc Medicine, Inc. | -91.12 Million USD | 293.919% |
| Champions Oncology, Inc. | -7.35 Million USD | 2502.243% |
| REGENXBIO Inc. | -268.12 Million USD | 165.905% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 1748.684% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 416.933% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 553.558% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 254.524% |
| Vaxart, Inc. | -83.34 Million USD | 312.016% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 2174.047% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 512.929% |
| Cellectis S.A. | -106.62 Million USD | 265.728% |
| Longeveron Inc. | -21.02 Million USD | 940.311% |
| Repare Therapeutics Inc. | -116.22 Million USD | 252.042% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 165.98% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 333.603% |
| Revolution Medicines, Inc. | -487.18 Million USD | 136.271% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 2756.479% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 502.032% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 336.907% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 353.765% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 1704.841% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 95.898% |
| Denali Therapeutics Inc. | -196.69 Million USD | 189.837% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 2141.306% |
| Veru Inc. | -93.78 Million USD | 288.425% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 857.465% |
| Cingulate Inc. | -22.75 Million USD | 876.429% |
| Passage Bio, Inc. | -108.38 Million USD | 263.032% |
| Context Therapeutics Inc. | -25.07 Million USD | 804.789% |
| Exicure, Inc. | -14.99 Million USD | 1278.374% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 185.754% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 535.265% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 1918.567% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 195.852% |
| Nuvalent, Inc. | -149.49 Million USD | 218.206% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 2250.658% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 299.151% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 950.626% |
| OmniAb, Inc. | -69.41 Million USD | 354.554% |
| Anew Medical, Inc. | -1.3 Million USD | 13684.223% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 1483.674% |
| Lipocine Inc. | -17.93 Million USD | 1085.497% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 357.92% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 332.048% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 564.104% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 547.059% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 889.443% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 130.475% |
| Ocugen, Inc. | -65.53 Million USD | 369.657% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 288.257% |
| Q32 Bio Inc. | -92.1 Million USD | 291.862% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 924.241% |
| Alumis Inc. Common Stock | -158.17 Million USD | 211.718% |
| Equillium, Inc. | -14.52 Million USD | 1316.837% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 383.16% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 2335.875% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1036.698% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 476.369% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 262.916% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 1576.264% |
| Dominari Holdings Inc. | -21.79 Million USD | 910.741% |
| Edesa Biotech, Inc. | -9.22 Million USD | 2016.01% |
| vTv Therapeutics Inc. | -25.5 Million USD | 792.922% |
| Bio-Techne Corporation | 206.68 Million USD | 14.504% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 145.138% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 7.978% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 233.59% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 560.288% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 216.948% |
| Nkarta, Inc. | -131.65 Million USD | 234.226% |
| BioCardia, Inc. | -11.64 Million USD | 1617.597% |
| Iterum Therapeutics plc | -47.46 Million USD | 472.27% |